Kekkaku(Tuberculosis)
Online ISSN : 1884-2410
Print ISSN : 0022-9776
ISSN-L : 0022-9776
CONTROLLED TRIAL OF ISONIAZID·ERIFAMPICIN·EETHAMBUTOL REGIMEN AND ISONIAZID·RIFAMPICIN·PYRAZINAMIDE REGIMEN IN THE PRIMARY CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS
Tuberculosis Research Committee RYOKEN
Author information
JOURNAL FREE ACCESS

1980 Volume 55 Issue 1 Pages 7-13

Details
Abstract
Clinical effect of two regimens, INH·ERFP·EEB regimen (EB group) and INH·RFP·PZA regimen (PZA group), were compared in the chemotherapy for previously untreated cavitary pulmonary tuber culosis patients with positive sputum. Each regimen was given for six months and followed by the same or another regimen that was selected freely by attending doctors.
1. The smear results of PZA group at 2 months and 3 months was 73.8% and 90.2%, respectively. These results were slightly better than that of EB group which was 68.0% and 77.0%, respectively, but the difference was not significant. The culture results of two regimens were almost similar, 70.3% in PZA group and 67.1% in EB group at 2 months, 94.9% and 88.9% at 3 months.
2. Improvement of X-ray findings of two regimens was also almost similar.
3. The total incidence of adverse reactions of any sort reported for 6 months was 75.3% in PZA group and 37.2% in EB group. The difference was significant. Hepatitis, elevation of level of uric acid and arthralgia associated with pyrazinamide were frequently found and there were significant difference between two regimens. Pyrazinamide was terminated in 24.7% of the patients, among them 11% by hepatitis.
Content from these authors
© THE JAPANESE SOCIETY FOR TUBERCULOSIS
Previous article Next article
feedback
Top